Puech Philippe, Potiron Eric, Lemaitre Laurent, Leroy Xavier, Haber Georges-Pascal, Crouzet Sebastien, Kamoi Kazumi, Villers Arnauld
Department of Radiology, Centre Hospitalier Régional Universitaire de Lille, France.
Urology. 2009 Nov;74(5):1094-9. doi: 10.1016/j.urology.2009.04.102. Epub 2009 Sep 20.
To determine the diagnostic performance of dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI) in the identification of intraprostatic cancer foci related to cancer volume at histopathology, in patients with clinically localized cancer treated by radical prostatectomy, with whole-mount histopathologic sections as the reference standard.
Eighty-three consecutive radical prostatectomy specimens from patients referred for a prostate-specific antigen elevation were correlated with prebiopsy MRI. MRI results ranked on a 5-point scale were correlated with the findings of histopathology maps in 8 prostate sectors, including volume, largest surface area, and percentage of Gleason grade 4/5. The area under the receiver operating characteristic curve was used.
Median prostate-specific antigen was 8.15 ng/mL. DCE-MRI was suspicious in 55 (66%) out of 83 patients. A separate cancer foci (mean 2.55 per patient) was present in 212 (34%) of 664 octants and DCE-MRI was suspicious in 68 of 212. Sensitivity and specificity of DCE-MRI at score 3.4 or 5 for identification of cancer foci at any volume was 32% and 95%, respectively. For identification of cancer foci > 0.5 mL, the sensitivity and specificity were 86% and 94%, respectively, with the under the receiver operating characteristic curve of 0.874. Mean volume of DCE-MRI detected and missed cancers were 2.44 mL (0.02-14.5) and 0.16 mL (0.005-2.4), respectively. Sensitivity and specificity of DCE-MRI for identification of > 10% of Gleason grade 4/5 were 81% and 82%, respectively.
DCE-MRI can accurately identify intraprostatic cancer foci. Possible applications are guidance for biopsies, selection of patients for watchful waiting, and focal treatment planning.
以全层组织病理学切片为参考标准,确定动态对比增强磁共振成像(DCE-MRI)在识别经根治性前列腺切除术治疗的临床局限性前列腺癌患者中与组织病理学癌体积相关的前列腺内癌灶方面的诊断性能。
对83例因前列腺特异性抗原升高而接受治疗的患者的连续根治性前列腺切除术标本与活检前MRI进行相关性分析。将MRI结果按5分制评分,并与8个前列腺区域的组织病理学图谱结果进行相关性分析,包括体积、最大表面积以及Gleason 4/5级的百分比。采用受试者操作特征曲线下面积进行分析。
前列腺特异性抗原中位数为8.15 ng/mL。83例患者中有55例(66%)DCE-MRI表现可疑。664个八分象限中有212个(34%)存在单独的癌灶(平均每位患者2.55个),其中212个中有68个DCE-MRI表现可疑。DCE-MRI评分为3、4或5时,识别任何体积癌灶的敏感性和特异性分别为32%和95%。对于识别体积>0.5 mL的癌灶,敏感性和特异性分别为86%和94%,受试者操作特征曲线下面积为0.874。DCE-MRI检测到的癌灶和漏诊癌灶的平均体积分别为2.44 mL(0.02 - 14.5)和0.16 mL(0.005 - 2.4)。DCE-MRI识别Gleason 4/5级>10%的敏感性和特异性分别为81%和82%。
DCE-MRI能够准确识别前列腺内癌灶。其可能的应用包括活检引导、选择观察等待的患者以及局部治疗规划。